6 days ago
2
The U.S. Food and Drug Administration (U.S. FDA) has issued a informing missive to Zydus Lifesciences relating to the company’s formulation manufacturing installation successful Baddi, Himachal Pradesh.
“The connection references method observations regarding the usage of purified talc that did not conscionable the existent United States Pharmacopeia (USP) requirements,” the institution said successful a filing connected Wednesday.
The informing missive “does not pertain to immoderate onsite inspection of the installation by the U.S. FDA.” It was issued successful effect to petition for records nether a Section of the Federal Food, Drug and Cosmetic Act. The institution believes that the informing missive volition not interaction existent operations and supplies from the Baddi site, Zydus said.
The manufacturing installation was past subjected to an on-site inspection by the U.S. FDA successful August 2025. Subsequent to the decision of the inspection, the institution received the constitution inspection study (EIR) successful October 2025, with the last compliance presumption classified arsenic Voluntary Action Indicated (VAI).
